McNeill Jonathan has filed 55 insider transactions across 2 companies since January 2023.
Most recent transaction: a grant/award of 6000 shares of CRESCENT BIOPHARMA, INC. ($CBIO) on December 15, 2025.
Activity breakdown: 0 open-market purchases and 30 sales.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dec. 15, 2025 | CRESCENT BIOPHARMA, INC. | $CBIO | McNeill Jonathan | President and COO | A | Ordinary Shares | 6000 | $0.00 | 159,707.0000 | 13,892,516 | 3.90% | 0.04% |
| Dec. 15, 2025 | CRESCENT BIOPHARMA, INC. | $CBIO | McNeill Jonathan | President and COO | A | Stock Option (Right to Buy) | 78029 | $0.00 | 78,029.0000 | 13,892,516 | 9999.99% | 0.56% |
| Dec. 15, 2025 | CRESCENT BIOPHARMA, INC. | $CBIO | McNeill Jonathan | President and COO | A | Ordinary Shares | 19507 | $0.00 | 153,707.0000 | 13,892,516 | 14.54% | 0.14% |
| Dec. 8, 2025 | CRESCENT BIOPHARMA, INC. | $CBIO | McNeill Jonathan | President and COO | A | Stock Option (Right to Buy) | 172836 | $0.00 | 172,836.0000 | 13,892,516 | 9999.99% | 1.24% |
| Aug. 19, 2024 | Dyne Therapeutics, Inc. | $DYN | McNeill Jonathan | Chief Business Officer | S | Common Stock | 2400 | $45.01 | 132,411.0000 | 0 | 1.78% | 0.00% |
| Aug. 19, 2024 | Dyne Therapeutics, Inc. | $DYN | McNeill Jonathan | Chief Business Officer | S | Common Stock | 305 | $46.00 | 132,106.0000 | 0 | 0.23% | 0.00% |
| June 11, 2024 | Dyne Therapeutics, Inc. | $DYN | McNeill Jonathan | Chief Business Officer | S | Common Stock | 1823 | $31.34 | 134,811.0000 | 0 | 1.33% | 0.00% |
| May 16, 2024 | Dyne Therapeutics, Inc. | $DYN | McNeill Jonathan | Chief Business Officer | S | Common Stock | 2279 | $28.20 | 137,129.0000 | 0 | 1.63% | 0.00% |
| May 16, 2024 | Dyne Therapeutics, Inc. | $DYN | McNeill Jonathan | Chief Business Officer | S | Common Stock | 495 | $28.59 | 136,634.0000 | 0 | 0.36% | 0.00% |
| July 11, 2023 | Dyne Therapeutics, Inc. | $DYN | McNeill Jonathan | Chief Business Officer | A | Stock option (right to buy) | 35000 | $0.00 | 35,000.0000 | 0 | 9999.99% | 0.00% |
| March 8, 2024 | Dyne Therapeutics, Inc. | $DYN | McNeill Jonathan | Chief Business Officer | S | Common Stock | 689 | $27.31 | 141,184.0000 | 0 | 0.49% | 0.00% |
| March 11, 2024 | Dyne Therapeutics, Inc. | $DYN | McNeill Jonathan | Chief Business Officer | M | Common Stock | 17825 | $5.54 | 159,009.0000 | 0 | 12.63% | 0.00% |
| March 11, 2024 | Dyne Therapeutics, Inc. | $DYN | McNeill Jonathan | Chief Business Officer | S | Common Stock | 17825 | $25.48 | 141,184.0000 | 0 | 11.21% | 0.00% |
| March 11, 2024 | Dyne Therapeutics, Inc. | $DYN | McNeill Jonathan | Chief Business Officer | S | Common Stock | 1776 | $25.71 | 139,408.0000 | 0 | 1.26% | 0.00% |
| March 8, 2024 | Dyne Therapeutics, Inc. | $DYN | McNeill Jonathan | Chief Business Officer | M | Stock option (right to buy) | 86159 | $0.00 | 12,309.0000 | 0 | 87.50% | 0.00% |
| March 8, 2024 | Dyne Therapeutics, Inc. | $DYN | McNeill Jonathan | Chief Business Officer | M | Stock option (right to buy) | 3841 | $0.00 | 17,825.0000 | 0 | 17.73% | 0.00% |
| March 11, 2024 | Dyne Therapeutics, Inc. | $DYN | McNeill Jonathan | Chief Business Officer | M | Stock option (right to buy) | 17825 | $0.00 | 0.0000 | 0 | 100.00% | 0.00% |
| March 8, 2024 | Dyne Therapeutics, Inc. | $DYN | McNeill Jonathan | Chief Business Officer | S | Common Stock | 54648 | $26.72 | 141,873.0000 | 0 | 27.81% | 0.00% |
| March 8, 2024 | Dyne Therapeutics, Inc. | $DYN | McNeill Jonathan | Chief Business Officer | S | Common Stock | 34663 | $25.46 | 196,521.0000 | 0 | 14.99% | 0.00% |
| March 8, 2024 | Dyne Therapeutics, Inc. | $DYN | McNeill Jonathan | Chief Business Officer | M | Common Stock | 3841 | $5.54 | 231,184.0000 | 0 | 1.69% | 0.00% |
| March 8, 2024 | Dyne Therapeutics, Inc. | $DYN | McNeill Jonathan | Chief Business Officer | M | Common Stock | 86159 | $5.54 | 227,343.0000 | 0 | 61.03% | 0.00% |
| March 7, 2024 | Dyne Therapeutics, Inc. | $DYN | McNeill Jonathan | Chief Business Officer | S | Common Stock | 2434 | $25.85 | 141,184.0000 | 0 | 1.69% | 0.00% |
| March 1, 2024 | Dyne Therapeutics, Inc. | $DYN | McNeill Jonathan | Chief Business Officer | S | Common Stock | 8715 | $29.06 | 145,060.0000 | 0 | 5.67% | 0.00% |
| March 1, 2024 | Dyne Therapeutics, Inc. | $DYN | McNeill Jonathan | Chief Business Officer | S | Common Stock | 1442 | $29.70 | 143,618.0000 | 0 | 0.99% | 0.00% |
| Feb. 29, 2024 | Dyne Therapeutics, Inc. | $DYN | McNeill Jonathan | Chief Business Officer | M | Stock option (right to buy) | 4268 | $0.00 | 24,260.0000 | 0 | 14.96% | 0.00% |
| March 1, 2024 | Dyne Therapeutics, Inc. | $DYN | McNeill Jonathan | Chief Business Officer | M | Stock option (right to buy) | 24260 | $0.00 | 0.0000 | 0 | 100.00% | 0.00% |
| Feb. 29, 2024 | Dyne Therapeutics, Inc. | $DYN | McNeill Jonathan | Chief Business Officer | M | Common Stock | 4268 | $0.73 | 147,886.0000 | 0 | 2.97% | 0.00% |
| Feb. 29, 2024 | Dyne Therapeutics, Inc. | $DYN | McNeill Jonathan | Chief Business Officer | S | Common Stock | 4268 | $27.50 | 143,618.0000 | 0 | 2.89% | 0.00% |
| March 1, 2024 | Dyne Therapeutics, Inc. | $DYN | McNeill Jonathan | Chief Business Officer | S | Common Stock | 14103 | $28.25 | 153,775.0000 | 0 | 8.40% | 0.00% |
| March 1, 2024 | Dyne Therapeutics, Inc. | $DYN | McNeill Jonathan | Chief Business Officer | M | Common Stock | 24260 | $0.73 | 167,878.0000 | 0 | 16.89% | 0.00% |
| Jan. 26, 2024 | Dyne Therapeutics, Inc. | $DYN | McNeill Jonathan | Chief Business Officer | S | Common Stock | 19822 | $24.52 | 143,796.0000 | 0 | 12.11% | 0.00% |
| Jan. 26, 2024 | Dyne Therapeutics, Inc. | $DYN | McNeill Jonathan | Chief Business Officer | M | Common Stock | 20000 | $0.73 | 163,618.0000 | 0 | 13.93% | 0.00% |
| Jan. 26, 2024 | Dyne Therapeutics, Inc. | $DYN | McNeill Jonathan | Chief Business Officer | S | Common Stock | 178 | $25.14 | 143,618.0000 | 0 | 0.12% | 0.00% |
| Jan. 26, 2024 | Dyne Therapeutics, Inc. | $DYN | McNeill Jonathan | Chief Business Officer | M | Stock option (right to buy) | 20000 | $0.00 | 28,528.0000 | 0 | 41.21% | 0.00% |
| Jan. 4, 2024 | Dyne Therapeutics, Inc. | $DYN | McNeill Jonathan | Chief Business Officer | M | Common Stock | 2009 | $0.73 | 145,627.0000 | 0 | 1.40% | 0.00% |
| Jan. 4, 2024 | Dyne Therapeutics, Inc. | $DYN | McNeill Jonathan | Chief Business Officer | S | Common Stock | 2009 | $18.04 | 143,618.0000 | 0 | 1.38% | 0.00% |
| Jan. 3, 2024 | Dyne Therapeutics, Inc. | $DYN | McNeill Jonathan | Chief Business Officer | M | Stock option (right to buy) | 17991 | $0.00 | 50,537.0000 | 0 | 26.25% | 0.00% |
| Jan. 4, 2024 | Dyne Therapeutics, Inc. | $DYN | McNeill Jonathan | Chief Business Officer | M | Stock option (right to buy) | 2009 | $0.00 | 48,528.0000 | 0 | 3.98% | 0.00% |
| Jan. 3, 2024 | Dyne Therapeutics, Inc. | $DYN | McNeill Jonathan | Chief Business Officer | S | Common Stock | 10300 | $19.03 | 143,618.0000 | 0 | 6.69% | 0.00% |
| Jan. 3, 2024 | Dyne Therapeutics, Inc. | $DYN | McNeill Jonathan | Chief Business Officer | S | Common Stock | 7691 | $18.34 | 153,918.0000 | 0 | 4.76% | 0.00% |
| Jan. 3, 2024 | Dyne Therapeutics, Inc. | $DYN | McNeill Jonathan | Chief Business Officer | M | Common Stock | 17991 | $0.73 | 161,609.0000 | 0 | 12.53% | 0.00% |
| Jan. 2, 2024 | Dyne Therapeutics, Inc. | $DYN | McNeill Jonathan | Chief Business Officer | S | Common Stock | 11900 | $13.10 | 143,618.0000 | 0 | 7.65% | 0.00% |
| Dec. 11, 2023 | Dyne Therapeutics, Inc. | $DYN | McNeill Jonathan | Chief Business Officer | S | Common Stock | 1245 | $10.72 | 155,518.0000 | 0 | 0.79% | 0.00% |
| Nov. 15, 2023 | Dyne Therapeutics, Inc. | $DYN | McNeill Jonathan | Chief Business Officer | A | Stock Option (right to buy) | 37445 | $0.00 | 37,445.0000 | 0 | 9999.99% | 0.00% |
| Nov. 15, 2023 | Dyne Therapeutics, Inc. | $DYN | McNeill Jonathan | Chief Business Officer | A | Common Stock | 96158 | $0.00 | 156,763.0000 | 0 | 158.66% | 0.00% |
| Sept. 18, 2023 | Dyne Therapeutics, Inc. | $DYN | McNeill Jonathan | Chief Business Officer | S | Common Stock | 1261 | $9.41 | 60,605.0000 | 0 | 2.04% | 0.00% |
| Sept. 12, 2023 | Dyne Therapeutics, Inc. | $DYN | McNeill Jonathan | Chief Business Officer | S | Common Stock | 1266 | $10.41 | 61,866.0000 | 0 | 2.01% | 0.00% |
| June 13, 2023 | Dyne Therapeutics, Inc. | $DYN | McNeill Jonathan | See Remarks | S | Common Stock | 1259 | $12.43 | 63,132.0000 | 0 | 1.96% | 0.00% |
| June 12, 2023 | Dyne Therapeutics, Inc. | $DYN | McNeill Jonathan | See Remarks | S | Common Stock | 1000 | $13.00 | 64,391.0000 | 0 | 1.53% | 0.00% |
| March 14, 2023 | Dyne Therapeutics, Inc. | $DYN | McNeill Jonathan | See Remarks | S | Common Stock | 1209 | $13.33 | 65,391.0000 | 0 | 1.82% | 0.00% |
| March 13, 2023 | Dyne Therapeutics, Inc. | $DYN | McNeill Jonathan | See Remarks | S | Common Stock | 1000 | $13.00 | 66,600.0000 | 0 | 1.48% | 0.00% |
| Jan. 18, 2023 | Dyne Therapeutics, Inc. | $DYN | McNeill Jonathan | See Remarks | M | Common Stock | 10000 | $0.73 | 77,600.0000 | 0 | 14.79% | 0.00% |
| Jan. 18, 2023 | Dyne Therapeutics, Inc. | $DYN | McNeill Jonathan | See Remarks | S | Common Stock | 10000 | $14.03 | 67,600.0000 | 0 | 12.89% | 0.00% |
| Jan. 18, 2023 | Dyne Therapeutics, Inc. | $DYN | McNeill Jonathan | See Remarks | M | Stock Option (right to buy) | 10000 | $0.00 | 68,528.0000 | 0 | 12.73% | 0.00% |
| Jan. 9, 2023 | Dyne Therapeutics, Inc. | $DYN | McNeill Jonathan | See Remarks | S | Common Stock | 30150 | $11.57 | 67,600.0000 | 0 | 30.84% | 0.00% |